Specialized CRO Services ChanTest’s focus on ion channel and GPCR safety testing positions it as a critical partner for pharmaceutical and biotech companies seeking expertise in nonclinical drug safety, offering opportunities to expand services in these niche areas.

Trusted Industry Reputation With a proven track record of being the most trusted provider in ion channel screening since 2006, ChanTest’s reputation can be leveraged to attract new clients looking for reliable and high-quality safety testing solutions.

Comprehensive Testing Library The company's extensive library of validated ion channel cell lines and cardiac risk assessment services provides a significant selling point for clients needing thorough nonclinical safety evaluations, suggesting potential for cross-selling additional testing services.

Growing Market Presence Although the company operates with a relatively small team, its longstanding reputation and specialized offerings present opportunities to target mid-size and large pharma firms aiming to outsource complex safety assessments, especially in cardiac risk.

Potential for Expansion With revenue between 1M and 10M and a strong niche focus, there is potential to grow through strategic partnerships, service expansion, and by capitalizing on increasing pharma investment in safety and cardiac assay testing.